EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome

Agni M Konitsioti iD, Rafael Grajewski, Mark Schlamann, Michael Schroeter, Gereon R Fink, Clemens Warnke

European Journal of Neurology · 2025-03 · 32 (3)

DOI: 10.1111/ene.70103 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Neurology, online erschienen am 03.03.2025. Verfasst von Agni M Konitsioti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Susac Syndrome, Natalizumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Susac syndrome is a rare autoimmune endotheliopathy that affects the central nervous system, retina, and inner ear, characterized by encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. Due to the heterogeneity of its presentation, early diagnosis, and treatment remain challenging. Objective/Methods To evaluate the clinical outcomes and radiological responses in two patients with Susac syndrome treated with natalizumab in an off‐label therapeutic approach, clinical assessments and serial magnetic resonance imaging (MRI) were performed over a follow‐up period of up to 22 months to monitor disease progression and treatment response.

Results

Both patients demonstrated clinical stabilization with reduced MRI and retinal angiography disease activity. Treatment was well tolerated, and no significant adverse events were reported during observation.

Discussion

Natalizumab may constitute a potential off‐label therapeutic for Susac syndrome. Further studies are warranted to assess its efficacy and safety in this rare condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Susac SyndromeNatalizumabHumansFemaleAdultMagnetic Resonance ImagingTreatment Outcome

Stichwörter der Autor:innen

DMTMRIneuroimmunologyneuroinflammationneuroopthalmologysusacvasculitis

Substanzen

Natalizumab

Autor:innen und Institutionen

  • Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Department of Ophthalmology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Department of Radiology and Neuroradiology, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
  • Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM3), Research Center Jülich, Jülich, Germany.
  • Department of Neurology, University Hospital Marburg, Marburg, Germany.

ORCID-Profile: Agni M Konitsioti

Zitieren

APA

Konitsioti, A. M., Grajewski, R., Schlamann, M., Schroeter, M., Fink, G. R., & Warnke, C. (2025). Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome. European Journal of Neurology, 32(3). https://doi.org/10.1111/ene.70103

Vancouver

Konitsioti AM, Grajewski R, Schlamann M, Schroeter M, Fink GR, Warnke C. Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome. European Journal of Neurology. 2025;32(3). doi:10.1111/ene.70103

BibTeX
@article{Konitsioti2025,
  author = {Konitsioti, Agni M and Grajewski, Rafael and Schlamann, Mark and Schroeter, Michael and Fink, Gereon R and Warnke, Clemens},
  title = {Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {3},
  doi = {10.1111/ene.70103}
}
Kostenlos starten →